NCT00864552View on ClinicalTrials.gov

International PMS Study - KOGENATE Bayer

CompletedOBSERVATIONAL

Enrollment

200

Participants

Timeline

Start Date

December 31, 2002

Study Completion Date

December 31, 2005

Conditions

Hemophilia A

Interventions

DRUG

Kogenate (BAY14-2222)

Patients with severe haemophilia A (\<2% FVIII:C baseline level) treated with Kogenate Bayer as their only source of recombinant FVIII

Trial Locations (10)

Unknown

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Many Locations

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY

NCT00864552 - International PMS Study - KOGENATE Bayer | Biotech Hunter | Biotech Hunter